Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 82 clinical trials
SOLIDARITY Finland Plus Long-COVID

The SOLIDARITY PLUS Finland Long-COVID trial aims to assess the long-term effects of imatinib and infliximab, used during acute hospitalization due to COVID-19-infection, on long-COVID symptoms

  • 0 views
  • 17 May, 2022
  • 1 location
Temozolomide (TMZ) In Advanced Succinate Dehydrogenase (SDH)-Mutant/Deficient Gastrointestinal Stromal Tumor (GIST)

Funding Source - FDA OOPD FDA-approved products for patients with unresectable or metastatic GIST include therapies such as imatinib and sunitinib. Although there are FDA-approved

primary cancer
imatinib
renal function
renal function test
cancer
  • 11 views
  • 12 Feb, 2022
  • 4 locations
(Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors

part of the study will enroll approximately 388 patients who are intolerant to, or who failed prior treatment with imatinib only and will compare the efficacy of CGT9486 plus sunitinib to sunitinib

tyrosine
sunitinib
measurable disease
  • 0 views
  • 02 Jun, 2022
  • 8 locations
Evaluation of a Cardiovascular Active Prevention in Chronic Myeloid Leukemia on the Cardiovascular Morbi-mortality

approval of imatinib, additional tyrosine kinase inhibitors (TKIs) have been approved by the European Medicine Agency, including the second-generation TKIs nilotinib, dasatinib, and bosutinib and the third

bosutinib
imatinib
leukemia
ponatinib
cancer
  • 1 views
  • 13 Feb, 2021
  • 1 location
A Study of THE-630 in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)

This study will assess the safety, efficacy, and pharmacokinetics of THE-630 in participants with advanced gastrointestinal stromal tumors (GIST).

treatment regimen
primary cancer
immunostimulants
cancer
neuropathy
  • 0 views
  • 16 May, 2022
  • 4 locations
Genomics-Based Target Therapy for Children With Relapsed or Refractory Malignancy

The purpose of this study is to evaluate the efficacy and feasibility of combination chemotherapy with target agents according to the result of targeted deep sequencing in pediatric patients with relapsed/refractory solid tumor or AML.

fludarabine
ifosfamide
cancer
imatinib
etoposide
  • 0 views
  • 24 Jan, 2021
  • 1 location
A Study of NB003 in Patients With Advanced Malignancies

This a A Phase 1, Open-label, Multicenter Study to Assess the Safety, Tolerability, and Pharmacokinetics of NB003 in Subjects with Advanced Solid Tumors

  • 0 views
  • 25 Mar, 2022
  • 2 locations
Single Agent Regorafenib in First-line for Metastatic/Unresectable KIT/PDGFR Wild Type GIST (REGISTRI)

Evaluate the treatment with regorafenib in patients with metastatic and/or unresectable KIT/PDGFR wild type GIST in the first line setting.

KIT
lipase
renal function
measurable disease
regorafenib
  • 0 views
  • 26 Jan, 2022
  • 15 locations
Study of Axitinib (AG-013736) With Evaluation of the VEGF-pathway in Pheochromocytoma/Paraganglioma

Primary Objective: To determine the response rate (RR) of metastatic or locally advanced pheochromocytoma/paraganglioma to axitinib administered daily. Secondary Objectives: Determine the progression-free survival. In an exploratory manner examine the extent of activation of the VEGFR pathway in pheochromocytoma/paraganglioma using a semi-quantitative immunohistochemistry assay and examine the relationship with response …

axitinib
iobenguane
lipase
adrenal pheochromocytoma
neutrophil count
  • 1 views
  • 07 Feb, 2022
  • 1 location
Interest of PHARMaceutical Conciliation to Understand Drug Interactions, Phytotherapy, and Targeted Therapies in Chronic Myeloid Leukemia (PHARM-LMC)

The aim of this trial is therefore to identify concomitant treatments with taking Tyrosine Kinase Inhibitor (=TKI) in the indication of Chronic Myeloid Leukemia (CML), whatever the stage of the disease, via pharmaceutical conciliation. These concomitant treatments as well as their dosages will be correlated with the TKI dosage since …

nilotinib
bosutinib
imatinib
kinase inhibitor
tyrosine
  • 0 views
  • 10 Mar, 2022
  • 1 location